Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Short term Debt (2016 - 2019)

Outlook Therapeutics (OTLK) has disclosed Short term Debt for 5 consecutive years, with $6.7 million as the latest value for Q3 2019.

  • Quarterly Short term Debt rose 9976.71% to $6.7 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Sep 2019, up 9976.71% year-over-year, with the annual reading at $6.7 million for FY2019, 9976.71% up from the prior year.
  • Short term Debt for Q3 2019 was $6.7 million at Outlook Therapeutics, up from $1.0 million in the prior quarter.
  • The five-year high for Short term Debt was $12.5 million in Q1 2018, with the low at $52600.0 in Q3 2017.
  • Average Short term Debt over 5 years is $3.2 million, with a median of $747547.5 recorded in 2015.
  • Peak annual rise in Short term Debt hit 16632.49% in 2018, while the deepest fall reached 99.25% in 2018.
  • Over 5 years, Short term Debt stood at $742646.0 in 2015, then plummeted by 85.14% to $110394.0 in 2016, then rose by 7.58% to $118759.0 in 2017, then surged by 7527.31% to $9.1 million in 2018, then decreased by 26.04% to $6.7 million in 2019.
  • According to Business Quant data, Short term Debt over the past three periods came in at $6.7 million, $1.0 million, and $7.6 million for Q3 2019, Q2 2019, and Q1 2019 respectively.